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The purpose of this study was to develop and test a struc-
tural model explaining medication compliance of schiz-
ophrenia. From a review of the literature, a hypothetical model
was developed based on the conceptual framework of the
Health Belief Model with medication knowledge, symptom
severity and social support as the exogenous variables, and
perceived benefits, perceived barriers, substance use and
medication compliance as the endogenous variables. Data was
collected at various mental health facilities, including psychi-
atric outpatient clinics of general hospitals and community
mental health centers, between March and May, 2001. A
structured questionnaire was used by one- on- one interviews
to collect data on 208 schizophrenic patients. Well established
measurement instruments, with confirmed reliability, were
used to assess each method variable. As a result of covariance
structural analysis, the hypothetical model was found not to fit
the empirical data well, so a parsimonious model was adopted
after modifying the model. The final model was able to explain
the 33% medication compliance. Medication knowledge,
social support and perceived benefits had significant effects on
medication compliance. The findings of this study address the
importance of medication education and social support to
promote medication compliance. It is also suggested that
various education programs and support groups are needed to
enhance medication compliance.
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INTRODUCTION
Medication compliance is essential in managing
the psychotic symptoms of schizophrenic patients.
However, it has been reported that 65.8% of
mentally ill patients had experiences of taking
their medication at different times and with dif-
ferent dosages from those prescribed by their
doctor.
1 Medication noncompliance leads to a re-
lapse of symptoms and rehospitalization. A re-
lapse rate of 16% over one year was reported
when schizophrenic patients took their medication
as their doctors ordered, but this was 74% when
the prescribed regimen was not followed.
2
Many variables influencing medication compli-
ance in the mentally ill have been identified from
prior studies. Medication knowledge,
3-5 symptom
severity,
6-8 social support,
9-11 perceived benefits
12-14
and barriers,
15-17 and substance abuse
18-19 have all
been well identified as variables influencing
medication noncompliance. When patients had no
knowledge of their medication, their psychiatric
symptoms were serious, but when social support
was received from their family, friends and health
care providers, medication noncompliance was
higher. Alcohol and drug use also interfere with
medication compliance.
Even though these variables are well known,
prior studies have only revealed the direct effects
of these variables on medication compliance; thus,
which variables are most influential and impor-
tant remain unknown. Therefore, the factors influ-
encing medication compliance, and to what degree,
either direct or indirect, needs to be examined.
Thus, the development of a comprehensive
model explaining chronic schizophrenic patients'
medication compliance is required. The more
variables included in the model, the higher the
explanation power. However, to develop a precise
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and concise model, it is necessary to involve the
most influential variables.
The purpose of this study was to develop a
comprehensive and parsimonious model expla-
ining a schizophrenic patients' medication compli-
ance. The model should have a theoretical basis,
so that it will be possible to enhance intervention
for increased medication compliance.
CONCEPTUAL FRAMEWORK AND A HYPO-
THETICAL MODEL
Conceptual framework
The conceptual framework of this study con-
sisted of variables identified through a review of
the literature as major factors directly or indirectly
influencing medication compliance. The concept
of Becker's (1974) health belief model,
20 in which
medication compliance is seen as a behavior for
improving one's health, was used (Fig. 1). This
model has two assumptions: First, that one has a
need to avoid or recover from illness; second, one
performs a specific behavior to prevent an illness.
The Health Belief Model is applicable and useful
for psychiatric patients as they perform specific
behaviors, such as taking their medication to get
over their mental illness.
Hypothetical model
The hypothetical model consisted of three ex-
ogenous variables (medication knowledge, symp-
tom severity, and social support) and four endo-
genous variables (perceived benefit, perceived
barrier, substance use, and medication compli-
ance). The exogenous variables were independent
variables influencing the endogenous variables
either directly or indirectly. A total of 14 hypo-
thetical paths were established (Fig. 2).
MATERIALS AND METHODS
Subjects
The criteria for the study subjects were as follows:
1) Adult schizophrenic patients between the
age of 18 and 65 years, diagnosed with a
schizophrenia for at least 6 months.
2) A total score on the MMSE (Mini Mental
State Examination) over 25 in order to under-
stand the questions and correctly answer the
questionnaire.
3) Patients currently receiving psychiatric treat-
ment and taking medication.
4) Those currently residing in the community.
Hospitalized patients were not involved in
the sample as hospitalization affects medi-
cation compliance.
5) Patients had to verbally agreed to participate
in the study
Data collection
A pilot study was undertaken to ascertain if all
of the questions were understandable, then the
questionnaire was administered, on a on-to-one
basis, to 34 patients meeting the sample selection
Fig. 1. Conceptual framework.
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criteria before further study was conducted. Par-
ticipants were asked which questions they found
difficult or did not understand, with feedback on
those items used to modify the questions of easier
understanding.
Data were collected between March and May,
2001 through one-on-one interviews. To decrease
the sample error, eight provinces were used for
data, which was carried out in three general hos-
pital out patients' clinics, five community mental
health centers in different provinces, one com-
munity public health center, one day care center,
one doctor's clinic, and in patients' homes. Before
going to the mental health care facilities for data
collection, the purpose and method of the study
was explained to representatives of each facility
by letter and phone, and permission received for
collecting the data. The purpose of the study was
explained to each participant, and those agreeing
to participate were interviewed by the researcher.
A total of 244 patients meeting the subject selec-
tion criteria were interviewed and completed the
questionnaire. However, 36 participants' family
members were unable to be reached by phone to
measure medication compliance; thus, a total of
208 participant's questionnaires were used for the
analysis. A one-on-one interview for the question-
naire was undertaken by the researcher, which
took 30-40 minutes to complete.
Instruments
Medication knowledge
A total of 14 questions were asked relating to
medication knowledge, which was initially pre-
sented by Harbor et al. (1996).
21 Each question
was answered either 'yes', 'no', or 'don't know',
with total scores ranging from 0 to 14; the higher
the score, the greater the stress.
Symptom severity
Symptom severity was measured on the BPRS
(Brief Psychiatric Rating Scale) developed by
Overall et al. (1962)
.22 This questionnaire consisted
of 18 questions, divided into two parts. One part
measured the subjective symptoms, such as
degree of anxiety and depression, which consisted
of 9 questions. The second part also consisted of
9 questions, and measured the researchers' obser-
vations relating to slow movement and non
cooperation, etc. The score range of each question
was from 1 to 7, with the total scores ranging
from 18 to 126; the higher the score, the greater
the severity of the symptom. The Cronbach's
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X2: Medication effects X5: Subjective symptom X8: Friend support Y2: Cost and stigma Y5: Smoking
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alpha was 0.95 in this study.
Social support
Sarason's (1983) social support questionnaire
23
was used to measure family, friend and health
care provider support. A total of 8 questions were
asked, including the degree of satisfaction about
people they can trust, with each question having
a 6-point Likert style answer, from 'very unsat-
isfied' to 'very satisfied'. The total scores ranged
from 8 to 48; the higher the score, the greater the
degree of social support. The Cronbach's alpha in
the study was 0.92.
Perceived benefit
The perceived benefit refers to the good things
that can be attained by medication compliance,
which was measured using a modified Korean
version of Moon's (1990) health belief question-
naire
24 for Korean adults; 6 questions were in-
cluded in this questionnaire: symptom improve-
ment, decreasing the chance for relapse and
improvement of interpersonal relationship, etc.
having a 5-point Likert scale. The total scores
ranged from 6 to 30; the higher the score, the
greater the perceived benefits. The Cronbach's
alpha in this study was 0.84.
Perceived barrier
The perceived barriers refer to the difficulties
experienced by a person, which were addressed
by five items: medication side effects, price,
avoiding people's eye, visiting the hospital
regularly and trying to follow medication times.
This was measured using a modified Korean ver-
sion of Moon's (1990) health belief questionnaire
24
for Korean adults. Each question had a 5-point
Likert scale; with the answers ranging from 'very
likely' to 'unlikely'. The total scores ranged from
5 to 25; the higher the score, the greater the
perceived barriers. The Cronbach's alpha in this
study was 0.65.
Substance use
Substance refers to the psychoactive chemical
agents. The substance use questionnaire, devel-
oped by the Ministry of Culture and Athletics
(1996), was used.
25 The amount of alcohol and
cigarette uses per day and per month were mea-
sured, with the degree of alcohol use converted to
alcohol content; the higher the score, the greater
the participant's use of alcohol and cigarettes.
Medication compliance
Medication compliance refers to the behavior of
taking the correct medication and dose at the
correct time, as prescribed the participant's doc-
tors. This was measured in two ways, by self-
reporting and from family member's report. The
question, 'what age percent have you taken your
medication in the past one month? Answer 100%
if you took all medication as your doctor pre-
scribed', was asked to the patient. The question,
'what age percent has your ill family member
taken his/her medication in the past month?
Answer 100% if they took the medication as their
doctor prescribed', was asked to the participant's
family. When it was not possible to contact the
participant's family, a data collection phone in-
terview of the participant's family member was
carried out, with the patients' consent. The mean
of the two scores (patient and family) was the par-
ticipant's final medication compliance score; the
higher the score, the greater the medication com-
pliance.
Data analysis
The SPSS PC 11.0 Program was used for de-
scriptive statistics, and LISREL 8.12 for covariance
analysis for coincidence testing of the hypothetical
and modified models.
RESULTS
Demographic characters
There were 126 males (60.8%) and 82 females
(39.2%), with a mean age of 38.89 years and a
mean age at the onset of schizophrenia of 24.47
years. The mean illness and medication periods
were 11.4 and 9.4 years, respectively.
The effects and squared multiple correlation of the
hypothetical model
Medication knowledge, symptom severity, per-A Medication Compliance Structural Model in Chronic Schizophrenia
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ceived benefit and substance use had significant
direct effects on medication compliance, with an
explanation power of 89%; however, the indices of
the hypothetical model did not fit well. Therefore,
the model was modified (Table 1).
Testing hypothesis
The hypotheses including perceived benefits as
endogenous variables were:
Hypothesis 1 : 'The greater the medication
knowledge, the greater the perceived benefit' was
supported as a direct effect (r=0.10, t=3.18); signi-
ficant.
Hypothesis 2 : 'The more severe the symptoms,
the greater the perceived benefit' was not sup-
ported as a direct effect (r=0.03, t=0.29) ; not signi-
ficant.
Hypothesis 3 : 'The greater the social support,
the greater the perceived benefits' was supported
as a direct effect (r=0.54, t=8.08) ; significant.
The hypotheses including perceived barriers as
endogenous variables were:
Hypothesis 4 : 'The greater the medication
knowledge, the lower the perceived barriers' was
not supported as a direct effect (r=-0.07, t=-1.95);
significant.
Hypothesis 5 : 'The more severe the symptoms,
the greater the perceived barriers' was supported
as a direct effect (r=0.90, t=13.76); significant.
Hypothesis 6 : 'The greater the substance use,
the greater the perceived barriers' was not
supported, as this path was removed.
The hypotheses including substance use as an
endogenous variable were:
Hypothesis 7 : 'The more severe the symptoms,
the greater the substance use' was supported as a
direct effect (r=0.71, t=11.41); significant.
Hypothesis 8 : 'The greater the social support,
the lower the substance use' was not supported
(r=0.30, t=5.45) ; even though the statistical value
was effective, the direction of the effect coefficient
did not coincide.
The hypotheses including medication compli-
ance as an endogenous variable were:
Hypothesis 9 : 'The greater the medication
knowledge, the greater the medication compli-
ance' was supported as a direct effect (r=0.15,
Table 1. Effects of Endogenous Variables for the Hypothetical Model
Variables Direct Effect (t) Indirect Effect (t) Total Effect (t) SMC
Perceived benefit 0.96
Medication knowledge 1.79 (0.21)* 1.79 (8.66)*
Symptom severity -1.18 (0.12)* -1.18 (-9.55)*
Social support 0.00 (0.03) 0.00 (-0.09)
Perceived barrier 0.68
Medication knowledge -0.13 (0.19) -0.13 (-0.71)
Symptom severity 0.67 (0.11)* 0.03 (1.23) 0.70 (5.23)*
Substance use -0.14 (0.04) -0.14 (-1.61)
Substance use 0.95
Symptom severity 0.57 (0.06)* 0.57 (9.07)*
Social support 0.44 (0.07) 0.44 (6.21)*
Medication compliance 0.89
Medication knowledge 0.66 (0.87)* -13.65 (-5.44) 1.27 (3.45)*
Symptom severity -0.41 (0.32)* 10.14 (2.56) 9.73 (4.25)*
Social support 1.22 (0.34)* 5.72 (3.47) 6.94 (6.37)*
Perceived benefit -1.04 (0.51)* -1.04 (-2.40)*
Perceived barrier -0.04 (0.14) -0.04 (-0.75)
Substance use -2.16 (0.64)* -2.13 (-4.73)*
*p<.05 ( T >1.96)Mi-A Seo and Sung-Kil Min
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t=3.63); significant.
Hypothesis 10 : 'The more severe the symptoms,
the greater the medication compliance' was not
supported as a direct effect (r=-0.16, t=-1.80); not
significant.
Hypothesis 11 : 'The greater the social support,
the greater the medication compliance' was sup-
ported as a direct effect (r=0.48, t=7.72); signi-
ficant.
Hypothesis 12 : 'The greater the perceived ben-
efit, the greater the medication compliance' was
supported as a direct effect (r=0.20, t=2.14); signi-
ficant.
Hypothesis 13 : 'The lower the perceived bar-
riers, the greater the medication compliance' was
not supported, as this path was removed.
Hypothesis 14 : 'The greater the substance use,
the greater the medication compliance' was not
supported as a direct effect (r=0.07, t=1.87); not
significant.
Modifying the hypothetical model
The modifying process or the model considered
the conciseness, suitability, statistical significance
and theoretical meaning. The variables with a
correlation above 0.45 were used in the final an-
alysis, which was the case with most of the
variables in this study. Two paths were removed
as their effects were weak and insignificant, and
were found to decrease the suitability. These were
'how substance use affected perceived barriers'
and 'how perceived barriers affected medication'
(Fig. 3).
Fitness of the modified model
The chi-square value of the hypothetical model
was too high (842.92), and the other indices also
necessitated model modification. After modifica-
tion, all indices indicating suitability and concise-
ness fitted to the model well, with all ×2 (37.08,
df=18, p=0.005), GFI (0.98), AGFI (0.93), RMR (0.05),
NNFI (0.97) and CN (283.55) values (Table 2).
The effects and squared multiple correlation of
the modified model
Among the medication knowledge, symptom
severity and social support variables, which pre-
dict perceived benefits, medication knowledge
and social support had significant direct effects,
with an explanation power of 52%. Among the
medication knowledge, symptom severity and
Fig. 3. Path coefficient of the modified model.
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substance use variables, which predict the per-
ceived barriers, only symptom severity had a
significant direct effect, with an explanation
power of 71%. Both symptom severity and social
support had significant direct effects on substance
use, and both variables listed substance use as
64%. The endogenous variables, which predict
medication compliance, were medication knowl-
edge, symptom severity, social support, perceived
benefits and substance use. Three variables of
medication knowledge, social support, and per-
ceived benefits had significant direct effects on
medication compliance, with an explanation
power of 33%; social support had the strongest
direct effect among these variables (Table 3).
DISCUSSION
The model developed by structural equation
analysis has to reflect reality and have theoretical
validity.
26 The aim of this study was to develop
a concise, well fitted model to predict factors and
explain their direct and indirect effects on medica-
tion compliance. Many variables influencing me-
dication compliance in the mentally ill were
identified through an extensive literature review.
Among the variables identified, six were found
to have the most influence on medication compli-
ance. The endogenous variables were medication
knowledge, symptom severity and social support,
with perceived benefits, perceived barriers and
substance use as mediating variables. Medication
compliance of chronic schizophrenic patients was
directly affected by medication knowledge, social
support and perceived benefits, with an explana-
tion power for these variables of 33%.
Prior study results have not been consistent
with regards to medication knowledge directly
affecting medication compliance. One research
Table 2. Fitness of Indices
κ
2 df κ
2/df GFI AGFI RMR NNFI NFI CN
Hypothetical model 842.92 (p=0.00) 19 44.36 0.70 0.13 0.84 0.81 0.25 13.92
Modified model 37.08 (p=0.005) 18 2.06 0.98 0.93 0.05 0.97 0.98 283.55
Table 3. Effects of Endogenous Variables for the Modified Model
Variables Direct Effect (t) Indirect Effect (t) Total Effect (t) SMC
Perceived benefit 0.52
Medication knowledge 0.10 (3.18)* 0.10 (3.18)*
Symptom severity 0.03 (0.29) 0.03 (0.29)
Social support 0.54 (8.08) 0.54 (8.08)*
Perceived barrier 0.71
Medication knowledge -0.07 (-1.95) -0.07 (-1.95)
Symptom severity 0.90 (13.76)* -0.02 (-0.19) 0.88 (11.40)*
Substance use 0.64
Symptom severity 0.71 (11.41)* 0.71 (11.41)*
Social support 0.30 (5.45)* 0.30 (5.45)*
Medication compliance 0.33
Medication knowledge 0.15 (3.63)* 0.01 (2.65) 0.16 (3.87)*
Symptom severity -0.16 (-1.80) 0.05 (3.72) -0.11 (-2.44)*
Social support 0.48 (7.72)* 0.14 (-0.97) 0.72 (11.15)*
Perceived benefit 0.20 (2.14)* 0.38 (0.16) 0.58 (2.20)*
Substance use 0.07 (1.87) 0.07 (1.87)
*p<.05 ( T >1.96).Mi-A Seo and Sung-Kil Min
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report suggested that medication knowledge in-
creased after a medication education program,
which led to an increase in medication compli-
ance.
5 However, another study reported that me-
dication education to schizophrenic patients did
not change medication compliance, even though
their medication knowledge had increased.
27
Medication compliance was found to be directly
affected by medication knowledge in this study.
It is thought that most participants attended an
outpatient treatment care center, where they were
repeatedly educated about the effects and side
effects of the medication and the importance of
taking medication for preventing a relapse; thus,
they knew about their medication and it increased
compliance.
Social support has consistently been identified
as a reinforcement factor for medication compli-
ance through prior studies.
28,29 However, the ex-
tent to which social support predicts medication
compliance has not been identified. The finding of
this study, that social support was the most
powerful predictor of influences on medication
compliance in chronic schizophrenic patients, is
new. Thus, strengthen social support is suggested,
for which various strategies need to be developed
that involve families, friends and health care pro-
fessionals.
Perceived benefits come from the therapeutic
effects of the antipsychotic agents, improvement
in the symptoms, and relapse and rehospitaliza-
tion prevention, and are determining factors of
health behaviors. They can also be heightened by
medication education, and complying patients
have higher perceived benefits than noncompliant
patients.
30 From the findings in this study, it was
clear that the perceived benefits are the second
strongest variables for predicting medication com-
pliance. Thus, it is also suggested that the medi-
cation's positive rather than negative effects, such
as side effects, have to be reinforced.
Unlike other diseases, schizophrenic patients do
not take their medication, as they lose their
insight into illness and treatment. It was reported
that the degree of insight was consistently related
to the degree of medication compliance,
31 so is
suggested a variable that should be included in
further study.
Also, severe psychotic symptoms lead to in-
creases in medication dose and frequency, which
impede medication compliance.
32 Thus, symptom
severity was an important factor that could de-
crease medication compliance in schizophrenia.
However, this variable did not significantly pre-
dict medication compliance in this study. The
mean BPRS score in this study was 27.45, which
was very low in comparison to the original
median BPRS score of 72.0, suggesting the symp-
toms were not that severe in most of the par-
ticipants. The reason the BPRS was low was due
to all the study participants residing in the com-
munity, not a hospital, so their symptoms were
manageable and less severe. Thus, a very low
BPRS did not have a significant effect on medica-
tion compliance in this study.
Substance use has been identified in prior
studies as a major factor leading to medication
noncompliance and most patients in psychiatric
hospitals have a substance abuse history.
33,34 With
alcohol abuse, 62% of patients discontinued their
medication, which increased the medication non-
compliance eight fold.
35 The study participants'
amount of substance use was very low, so did not
significantly affect medication compliance in this
study. A small number of participants drank al-
cohol at a social drinking level. Cigarette smoking
was not that significant either. Because most
patients were involved in treatment settings, such
as community mental health centers, outpatient
clinics and public health centers, they knew it was
harmful to use substances while on medication
therapy.
Perceived barriers, such as health care cost, fear,
side effects and accessibility,
36 need to be over-
come before beginning healthy behavior. Per-
ceived barriers lead patients to believe that their
medication is not helpful and has no benefits.
37
However, perceived barriers did not significantly
influence medication compliance in this study.
The different results compared to prior studies
were due to the study participants characteristics
and cultural aspects. Chronic patients usually
know how to deal with the side effects, and were
under Medicaid support from the Korean govern-
ment, so payment for medicine was not a major
problem. Thus, it can be said that the difficulties
encountered with taking medication for chronic
schizophrenic patients were not significantA Medication Compliance Structural Model in Chronic Schizophrenia
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enough to decrease medication compliance.
In this study, medication knowledge, social
support and perceived benefits predicted both
direct and indirect medication compliance. Thus,
to strengthen medication compliance of chronic
schizophrenic patients residing in the community,
continuous education needs to be enhanced to
increase medication knowledge and social support
from families, health care persons, and friends.
The significance of this study lies in the devel-
opment of a basis for theory for schizophrenic
patients' medication compliance. However, our
results are limited, and do not apply to hospita-
lized schizophrenics or those not involved in a
treatment setting. Also, those patients that stay at
home, without the involvement of a treatment
setting, were not included in the study sample.
Thus, the model developed in the study can only
be applied to schizophrenic patients involved in
a treatment setting. It is suggested that these
patients should be included in a future study and
a model developed that can be applied to all
schizophrenic patients, irrespective of their envir-
onment. Developing various programs to enhance
patients' medication compliance, and many inter-
vention programs to heighten social support, have
been suggested.
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